JournalsHub
.online
Find My Journal
PM

Pamela N. Münster

University of California, San Francisco US

ORCID iD 0000-0002-2074-0984
731
Publications
19,709
Citations
67
H-Index
197
i10-Index
1.19
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

730 total

KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors PDF

David S. Hong, Marwan Fakih, John H. Strickler, Jayesh Desai, Gregory A. Durm et al. - New England Journal of Medicine, 2020
Cited by 1,661 OpenAlex

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma PDF

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal, Monica Mita, John W. Moroney et al. - JAMA Oncology, 2019
Cited by 553 OpenAlex

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC PDF

Paul C. Tumeh, Matthew D. Hellmann, Omid Hamid, Katy K. Tsai, Kimberly Loo et al. - Cancer Immunology Research, 2017
Cited by 558 OpenAlex

Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1- <sup>13</sup> C]Pyruvate PDF

Sarah J. Nelson, John Kurhanewicz, Daniel B. Vigneron, Peder E. Z. Larson, Andrea Harzstark et al. - Science Translational Medicine, 2013
Cited by 1,249 OpenAlex

Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy OA

S. Thomas, K. Thurn, E. Biçaku, D. Marchion, P. Münster - Breast Cancer Research and Treatment, 2011
Cited by 114 Semantic Scholar

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

Adil Daud, Ronald C. DeConti, Stephanie Andrews, P. Urbas, Adam I. Riker et al. - Journal of Clinical Oncology, 2008
Cited by 684 OpenAlex

Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. OA

E. Biçaku, D. Marchion, M. Schmitt, P. Münster - Cancer Research, 2008
Cited by 92 Semantic Scholar

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. OA

P. Münster, D. Marchion, E. Biçaku, M. Schmitt, J. Lee - Journal of Clinical Oncology, 2007
Cited by 220 Semantic Scholar

Development of histone deacetylase inhibitors for cancer treatment

D. Marchion, P. Münster - Expert Review of Anticancer Therapy, 2007
Cited by 155 Semantic Scholar

Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.

P. Münster, D. Marchion, A. Basso, N. Rosen - Cancer Research, 2002
Cited by 174 Semantic Scholar

Research Topics

Histone Deacetylase Inhibitors Research (98) Cancer Treatment and Pharmacology (89) Protein Degradation and Inhibitors (77) Cancer Immunotherapy and Biomarkers (69) Wnt/β-catenin signaling in development and cancer (64)

Affiliations

Northwestern University
US 2011 - 2011
University of Southern California
US 2013 - 2013
Novartis (Switzerland)
CH 2017 - 2017
Biogen (United States)
US 2010 - 2010
University of Minnesota
US 2013 - 2013

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now